Optimus Receives Tentative Approval from U.S. FDA for Brexpiprazole Tablets

Hyderabad (Telangana) [India], October 09: Optimus Pharma Private Limited today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for the generic equivalent of Rexulti® Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, of Otsuka Pharmaceutical Co., Ltd. Optimus Pharma’s approval for its Abbreviated New Drug Application (ANDA) BREXPIPRAZOLE Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, was received on October 8th, 2021. BREXPIPRAZOLE will be manufactured at Optimus Pharma’s Pashmylaram USFDA accredited facility in India.

BREXPIPRAZOLE Tablets (RLD: Rexulti® Tablets) had estimated annual sales of USD 1258 million in the U.S. (IQVIA MAT July 2021).

BREXPIPRAZOLE has a favourable antipsychotic profile in terms of improvement of cognitive performance and sleep patterns, as well as effects on affective states and potential to treat core symptoms in schizophrenia and major depressive disorder, including cognitive deficits with a low risk of adverse effects (extrapyramidal symptoms, metabolic complications, weight gain, akathisia potential) that are commonly encountered with other typical and second-generation antipsychotic drugs. From the studies done so far, it can be concluded that BREXPIPRAZOLE can be effective monotherapy for schizophrenia and as an adjunct to other antidepressant medications in major depressive disorder.

About Optimus Pharma

Optimus was established in the year 2004 as a custom synthesis laboratory by a team of techno-commercial experts. It is one of the fastest-growing Manufacturer in Active Pharmaceutical Ingredients (APIs) and Finished dosages. Over the last decade, we have been certified and audited by reputed Global Regulatory Agencies like USFDA, WHO, COFEPRIS, EMA, KFDA and AFM from PMDA Japan. Optimus Pharma is a vertically integrated pharmaceutical company engaged in the manufacturing of Solid Oral and semisolid formulations. We have successfully integrated our API and Formulation R&D teams, with the IP and Regulatory Affairs team in order to ensure a dynamic product portfolio. We help our customers serve global markets with technology based, innovative, cost effective & consumer friendly products of the highest quality.

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Tedco Education Sets Up Its New Campus Goodrich Tedco School of Bakey Arts in Association with Goodrich Carbohydrates and Chef Sahil Mehta

May 21: Over the past few years, the food services industry has emerged as a critical segment of the Indian economy. In fact, this vibrant industry has witnessed rapid growth in the recent past, and experts suggest that it will continue to grow in the coming years. Looking at this growth opportunity, Tedco Education, a […]

Read More
Business

InkQuills Publishing House- An Evolutionary and Approachable Go-to Solution for Writer and Authors

May 21: InkQuills Publishing House is India’s fastest growing self-publishing house. They have published more than 100+ books and have helped more than 2000+ authors realize their potential. InkQuills has a global network for paperback and eBook distribution. Their worldwide reach helps you gather a vast readership and develop a fan base in more than […]

Read More
Business

2nd day of the Cinetalkies, Azadi ka Amrit Mahotsav hosted by Sanskar Bharti concludes with aspiring smiles

Moderator- Raviraj Pramani, Durga Jasraj,Anu Malik,Bharat Bala discussing about Bharatiya Cinema Sangeet. ~it was an experience in its own way, Cinetalkies the one-of-a-kind seminar gave us stories worth remembering and the future outlook of the cinema industry~ Mumbai, 21 th May 2022: Sanskar Bharti, one of the well-known organsiation working towards the promotion of Indian art and […]

Read More